VE-cadherin mAbs inhibit growth of C6 glioma tumors.
C6 glioma (3 × 106 cells/mice) was injected subcutaneously into the right flank of nu/nu (CD-1)BR mice. The day after injection and every 3 days, mice received 50 μg/mouse of nonimmune IgG or an equal amount of BV14 or BV13 or DC101 (800 μg/mouse). (A) Immunofluorescence staining of C6 vessels using a rat anti–mouse-PECAM-1 mAb. Vessels present an enlarged lumen and irregular structure in control mice. In the 3 groups of treated mice, the vessels were reduced in number and size. (Magnification ×200.) (B) Time course of C6 tumor growth in animals treated with BV13, BV14, and DC101. All 3 mAbs inhibited C6 growth, but DC101 was the most effective. BV14 and BV13 showed a comparable activity. Data are means of 3 separate experiments performed in quintuplicate. SEM never exceeded 20% of the means. Higher doses of BV14 (up to 200 μg/mouse) showed similar results.
